TABLE 3.
Analysed gene-antidepressant-response pairs and actionability of CYP2D6 and CYP2C19 pharmacogenetics (N = 79).
| No | Case | Genotype-inferred phenotype | a Gene-antidepressant-response pairs | CYP2D6 genotype | CYP2C19 genotype | |||
|---|---|---|---|---|---|---|---|---|
| CYP2D6 | CYP2C19 | Actionable | Non-actionable | Actionable | Non-actionable | |||
| 1 | B1 | Intermediate | Rapid | CYP2D6-Amitriptyline-ADR | √ | N/A | N/A | |
| 2 | CYP2C19-Amitriptyline-ADR | N/A | N/A | √ | ||||
| 3 | B2 | Intermediate or poor | Intermediate | CYP2D6-Amitriptyline-ADR | √ | N/A | N/A | |
| 4 | CYP2C19-Amitriptyline-ADR | N/A | N/A | √ | ||||
| 5 | CYP2C19-Sertraline-ADR | N/A | N/A | √ | ||||
| 6 | B4 | Normal | Rapid | CYP2D6-Amitriptyline-ADR | √ | N/A | N/A | |
| 7 | CYP2C19-Amitriptyline-ADR | N/A | N/A | √ | ||||
| 8 | B5 | Normal | Normal | CYP2C19- Escitalopram-ADR | N/A | N/A | √ | |
| 9 | CYP2C19-Escitalopram-IE | N/A | N/A | √ | ||||
| 10 | B6 | Normal | Rapid | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | |
| 11 | B7 | Normal | Normal | CYP2D6-Nortriptyline-IE | √ | N/A | N/A | |
| 12 | CYP2D6-Paroxetine-IE | √ | N/A | N/A | ||||
| 13 | CYP2C19-Sertraline-IE | N/A | N/A | √ | ||||
| 14 | B8 | Intermediate | Rapid | CYP2D6-Clomipramine-ADR | √ | N/A | N/A | |
| 15 | CYP2D6-Clomipramine-IE | √ | N/A | N/A | ||||
| 16 | CYP2C19-Clomipramine-ADR | N/A | N/A | √ | ||||
| 17 | CYP2C19-Clomipramine-IE | N/A | N/A | √ | ||||
| 18 | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | ||||
| 19 | CYP2D6-Nortriptyline-IE | √ | N/A | N/A | ||||
| 20 | CYP2C19-Escitalopram-ADR | N/A | N/A | √ | ||||
| 21 | CYP2C19-Escitalopram-IE | N/A | N/A | √ | ||||
| 22 | B9 | Poor | Rapid | CYP2C19-Sertraline-ADR | N/A | N/A | √ | |
| 23 | B10 | Intermediate | Rapid | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | |
| 24 | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | ||||
| 25 | B11 | Intermediate | Normal | CYP2C19-Citalopram-ADR | N/A | N/A | √ | |
| 26 | B12 | Normal | Intermediate | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | |
| 27 | CYP2C19-Sertraline-ADR | N/A | N/A | √ | ||||
| 28 | B15 | Normal | Intermediate | CYP2D6-Venlafaxine-IE | √ | N/A | N/A | |
| 29 | CYP2C19-Sertraline-IE | N/A | N/A | √ | ||||
| 30 | B16 | Normal | Normal | CYP2D6-Venlafaxine-IE | √ | N/A | N/A | |
| 31 | CYP2D6-Nortriptyline-IE | √ | N/A | N/A | ||||
| 32 | B18 | Intermediate | Normal | CYP2D6-Venlafaxine-IE | √ | N/A | N/A | |
| 33 | B19 | Intermediate | Intermediate | CYP2D6-Paroxetine-ADR | √ | N/A | N/A | |
| 34 | CYP2C19-Escitalopram-ADR | N/A | N/A | √ | ||||
| 35 | B20 | Intermediate | Intermediate | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | |
| 36 | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | ||||
| 37 | CYP2C19-Escitalopram-IE | N/A | N/A | √ | ||||
| 38 | B21 | Normal | Normal | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | |
| 39 | B22 | Normal | Normal | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | |
| 40 | CYP2C19-Escitalopram-IE | N/A | N/A | √ | ||||
| 41 | CYP2C19-Sertraline-IE | N/A | N/A | √ | ||||
| 42 | B24 | Normal | Rapid | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | |
| 43 | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | ||||
| 44 | B26 | Normal | Normal | CYP2C19-Sertraline-ADR | N/A | N/A | √ | |
| 45 | B27 | Normal | Intermediate | CYP2C19-Citalopram-ADR | N/A | N/A | √ | |
| 46 | B28 | Normal | Poor | CYP2C19-Sertraline-IE | N/A | N/A | √ | |
| 47 | B29 | Normal | Normal | CYP2D6-Venlafaxine-IE | √ | N/A | N/A | |
| 48 | CYP2C19-Escitalopram-ADR | N/A | N/A | √ | ||||
| 49 | B30 | Intermediate | Intermediate | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | |
| 50 | CYP2C19-Escitalopram-ADR | N/A | N/A | √ | ||||
| 51 | CYP2C19-Escitalopram-IE | N/A | N/A | √ | ||||
| 52 | B31 | Normal | Rapid | CYP2C19-Sertraline-ADR | N/A | N/A | √ | |
| 53 | B32 | Intermediate | Intermediate | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | |
| 54 | CYP2C19-Citalopram-ADR | N/A | N/A | √ | ||||
| 55 | B33 | Intermediate | Intermediate | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | |
| 56 | B34 | Normal | Rapid | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | |
| 57 | CYP2D6-Venlafaxine-IE | √ | N/A | N/A | ||||
| 58 | CYP2C19-Citalopram-IE | N/A | N/A | √ | ||||
| 59 | CYP2C19-Escitalopram-IE | N/A | N/A | √ | ||||
| 60 | B36 | Intermediate | Normal | CYP2C19-Sertraline-ADR | N/A | N/A | √ | |
| 61 | B37 | Poor | Intermediate | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | |
| 61 | B38 | Ultrarapid | Normal | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | |
| 62 | CYP2C19-Escitalopram-ADR | N/A | N/A | √ | ||||
| 63 | B39 | Intermediate | Normal | CYP2C19-Escitalopram-IE | N/A | N/A | √ | |
| 64 | B40 | Normal | Normal | CYP2C19-Sertraline-ADR | N/A | N/A | √ | |
| 65 | B41 | Poor | Rapid | CYP2C19-Sertraline-ADR | N/A | N/A | √ | |
| 66 | B42 | Normal | Rapid | CYP2D6-Nortriptyline-ADR | √ | N/A | N/A | |
| 67 | CYP2D6-Venlafaxine-ADR | √ | N/A | N/A | ||||
| 68 | B43 | Intermediate | Intermediate | CYP2D6-Clomipramine-IE | √ | N/A | N/A | |
| 69 | CYP2C19-Clomipramine-IE | N/A | N/A | √ | ||||
| 70 | B44 | Normal | Ultrarapid | CYP2C19-Sertraline-ADR | N/A | N/A | √ | |
| 71 | B46 | Intermediate | Rapid | CYP2D6-Nortriptyline-IE | √ | N/A | N/A | |
| 73 | CYP2D6-Venlafaxine-IE | √ | N/A | N/A | ||||
| 74 | B48 | Intermediate | Rapid | CYP2C19-Sertraline-IE | N/A | N/A | √ | |
| 75 | B49 | Intermediate | Rapid | CYP2C19-Citalopram-ADR | N/A | N/A | √ | |
| 76 | B50 | Intermediate | Intermediate | CYP2C19-Citalopram-IE | N/A | N/A | √ | |
| 77 | CYP2C19-Escitalopram-ADR | N/A | N/A | √ | ||||
| 78 | B52 | Ultrarapid | Normal | CYP2C19-Sertraline-ADR | N/A | N/A | √ | |
| 79 | CYP2C19-Escitalopram-ADR | N/A | N/A | √ | ||||
a
ADR: adverse reactions, IE: ineffectiveness.